Scrutinizing selective Aurora Kinase A inhibition as a novel entry point for synthetic lethality in neuroblastoma Ghent University
Neuroblastoma is the most common extra-cranial solid tumor in children. Currently, despite multi-modal therapy, survival rates remain disappointingly low and survivors often suffer from major long-term effects of intensive therapy. Aurora kinase A (AURKA) has previously been identified as a potential drug target in high-risk neuroblastoma. However, despite the promising preclinical data for first generation inhibitors including alisertib, ...